Cargando…

Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-κB). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-κB expression in 120 patients: 102 with aden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeong, Jae-Heon, Cho, Byoung Chul, Shim, Hyo Sup, Kim, Hye-Ryun, Lim, Sun-Min, Kim, Se Kyu, Chung, Kyung Young, Islam, S.M. Bakhtiar Ul, Song, Jae Jin, Kim, Soo-Youl, Kim, Joo Hang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708070/ https://www.ncbi.nlm.nih.gov/pubmed/23853482 http://dx.doi.org/10.3346/jkms.2013.28.7.1005

Ejemplares similares

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Repeated Favorable Responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma
por: Kim, Eun-Young, et al.
Publicado: (2013)

Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition
por: Lee, Seon-Hyeong, et al.
Publicado: (2018)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer
por: Choi, Chang-Min, et al.
Publicado: (2011)

Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Ahn, Beung-Chul, et al.
Publicado: (2021)

New Insights into Development of Transglutaminase 2 Inhibitors as Pharmaceutical Lead Compounds
por: Kim, Soo-Youl
Publicado: (2018)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Neuroendocrine Differentiation in Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Chang, Youjin, et al.
Publicado: (2013)

Inhibiting Transglutaminase 2 Mediates Kidney Fibrosis via Anti-Apoptosis
por: Moon, Jong-Joo, et al.
Publicado: (2022)

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
por: Lim, Sun Min, et al.
Publicado: (2016)

Histological transformation from non-small cell to small cell lung carcinoma after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor
por: Kim, Woo-Jin, et al.
Publicado: (2015)

Effects of Transglutaminase 2 Inhibition on Ventilator-Induced Lung Injury
por: Suh, In Bum, et al.
Publicado: (2014)

Fms-Like Tyrosine Kinase 3-Independent Dendritic Cells Are Major Mediators of Th2 Immune Responses in Allergen-Induced Asthmatic Mice
por: Park, Sang Chul, et al.
Publicado: (2020)

Airway epithelial cells initiate the allergen response through transglutaminase 2 by inducing IL-33 expression and a subsequent Th2 response
por: Oh, Keunhee, et al.
Publicado: (2013)

A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2
por: Kim, Soo-Youl, et al.
Publicado: (2020)

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Lee, Jae Cheol, et al.
Publicado: (2013)

Epidermal Transglutaminase (TGase 3) Is the Autoantigen of Dermatitis Herpetiformis
por: Sárdy, Miklós, et al.
Publicado: (2002)

Ibuprofen Associated Acute Vanishing Bile Duct Syndrome and Toxic Epidermal Necrolysis in an Infant
por: Kim, Hye-young, et al.
Publicado: (2014)

A Novel Therapeutic Target in Inflammatory Uveitis: Transglutaminase 2 Inhibitor
por: Sohn, Joonhong, et al.
Publicado: (2010)

Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative
por: Lim, Sun Min, et al.
Publicado: (2016)

Epidermal Transglutaminase (TGase 3) Is Required for Proper Hair Development, but Not the Formation of the Epidermal Barrier
por: John, Susan, et al.
Publicado: (2012)

The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer
por: Cho, Jae-Won, et al.
Publicado: (2022)

Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
por: Kim, Hye Ryun, et al.
Publicado: (2020)

Genetic Variation in the Epidermal Transglutaminase Genes Is Not Associated with Atopic Dermatitis
por: Liedén, Agne, et al.
Publicado: (2012)

Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance
por: Kim, Suntae, et al.
Publicado: (2021)

Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma
por: Kang, Joon Hee, et al.
Publicado: (2020)

Involvement of Transglutaminase-2 in α-MSH-Induced Melanogenesis in SK-MEL-2 Human Melanoma Cells
por: Kim, Hyun Ji, et al.
Publicado: (2014)

The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
por: Sang, Yun Beom, et al.
Publicado: (2022)

Midazolam Ameliorates Hyperglycemia-Induced Glomerular Endothelial Dysfunction by Inhibiting Transglutaminase 2 in Diabetes
por: Seo, Jae-Ah, et al.
Publicado: (2022)

Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis
por: Kim, Chang Gon, et al.
Publicado: (2017)

Predicting treatment outcomes using (18)F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy
por: Kim, Chang Gon, et al.
Publicado: (2022)

Plasminogen Activator Inhibitor Type 1 (PAI-1) A15T Gene Polymorphism Is Associated with Prognosis in Patients with EGFR Mutation Positive Pulmonary Adenocarcinoma
por: Lim, Ju Eun, et al.
Publicado: (2013)

Clinical Features of Fixed Drug Eruption at a Tertiary Hospital in Korea
por: Jung, Jae-Woo, et al.
Publicado: (2014)

A case of extremely early cervical adenocarcinoma diagnosed only by endocervical curettage with macroscopic pelvic lymph node metastases
por: Jung, Jae Hak, et al.
Publicado: (2019)

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor
por: Kwon, Byoung Soo, et al.
Publicado: (2020)

Ethacrynic Acid Inhibits Sphingosylphosphorylcholine-Induced Keratin 8 Phosphorylation and Reorganization via Transglutaminase-2 Inhibition
por: Byun, Hyun Jung, et al.
Publicado: (2013)

Effect of the Recombinant Human Epidermal Growth Factor Ointment on Cutaneous Surgical Wounds Compared to Antibiotic Ointment
por: Ryu, Sook In, et al.
Publicado: (2021)

Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
por: Ahn, Beung-Chul, et al.
Publicado: (2019)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m1nm01dretjhq8oki0ribmjcdm